


Microfluidic-based clinical immunoanalyzer, 7/14

July 2014—Wako Life Sciences' μ TasWako i30 is available for the serum biomarkers lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) tests, which are intended for in vitro diagnostic use to help in the risk assessment of patients with chronic liver disease for development of hepatocellular carcinoma in conjunction with other laboratory findings, imaging studies, and clinical assessment.



The μ TasWako i30 enables miniaturization and integration of key analyzer processes for the sampling, mixing, separation, and detection of serum biomarkers in a microfluidic chip. The system uses immunochemical and electrophoretic techniques to achieve rapid, accurate, and sensitive assay results. The first test result is obtained nine minutes from starting the measurement; results thereafter are two minutes each. As a benchtop automated instrument, the μ TasWako i30 is designed for clinical laboratory settings and requires minimal setup time.

[Wako Life Sciences](#), 877-714-1924